FRAMINGHAM, MA -- (MARKET WIRE) -- February 14, 2007 -- Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) announced the completion of a private placement to accredited investors in December 2006 and January 2007 raising net proceeds of $2,368,038 for an aggregate of 3,213,632 shares of Class A common stock and 2,410,224 redeemable warrants. The purpose of the financing is to fund the ongoing Phase III pivotal clinical trial evaluating IoGen for the treatment of pain and tenderness associated with fibrocystic breast disease and working capital needs.
